5Albrt MA,Danielson E,Rifai N,et al. Effect of statin therapy on C -reactive protein levels the pravastatin inflammation/CRP evaluation (PRINCE); a randomized trial and cohort study. JAMA,2001,286( 1 ) :64 -70.
6Nomoto K, Oguchi S, Watanabe I, et al. Involvement of inflammation in a- cute coronary syndromes assessed by levels of high - sensitivity C - reactive protein, matrix metalloproteinase- 9 and soluble vascular- cell adhesion molecule - 1. J Cardiol,2003,42 (5) : 201 - 206.
7Kinlay S, Schwartz GG, Olsson AG, et al. High - dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulion,2003,108 ( 13 ) : 1560 - 1566.
8Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome[J]. Clin Chem, 2005,51:810-824.
9Trepels T, Zeiher AM, Fichtlscherer S. Acute coronary syndrome and inflammation biomarkers for diagnostics and risk stratification[J]. Herz, 2004,29:769-776.
10Heeschen C, Dimmeler S, Hamm CW, et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis[J]. J Am Coll Cardiol, 2005,45:229-237.
10Kleemann R,Verschuren L,de Booij BJ,et al.Evidence for antiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro[J].Blood,2004,103(11):4188-4194.
